{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation", "query": { "intervention": "Arm 1- Dose Escalation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 949, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T03:59:56.532Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01534598", "title": "FdCyd and THU for Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "FdCyd + THU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 59, "start_date": "2012-03-05", "completion_date": "2025-07-21", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 6, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534598" }, { "nct_id": "NCT01629758", "title": "Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms by Site" ], "interventions": [ { "name": "Denenicokin", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2012-06", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01629758" }, { "nct_id": "NCT05712278", "title": "A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukaemia" ], "interventions": [ { "name": "SAR445419", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-06-16", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 3, "location_summary": "Omaha, Nebraska • The Bronx, New York • Houston, Texas", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05712278" }, { "nct_id": "NCT01906385", "title": "Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "Rhenium Liposome Treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cerenome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2015-06-03", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 3, "location_summary": "Manhasset, New York • Dallas, Texas • San Antonio, Texas", "locations": [ { "city": "Manhasset", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01906385" }, { "nct_id": "NCT02671435", "title": "A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Monalizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 383, "start_date": "2016-02-22", "completion_date": "2027-07-30", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02671435" }, { "nct_id": "NCT05923190", "title": "Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-06-14", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05923190" }, { "nct_id": "NCT07024784", "title": "A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gynecologic Cancers", "Platinum-Sensitive Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer (PSOC)" ], "interventions": [ { "name": "IMGN151", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 377, "start_date": "2025-07-30", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 8, "location_summary": "Teaneck, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 5 more", "locations": [ { "city": "Teaneck", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Portland", "state": "Oregon" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT07024784" }, { "nct_id": "NCT00821652", "title": "Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod", "type": "DRUG" }, { "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nina Bhardwaj", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2009-02", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00821652" }, { "nct_id": "NCT02221960", "title": "A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent or Metastatic Solid Tumors" ], "interventions": [ { "name": "MEDI6383", "type": "BIOLOGICAL" }, { "name": "MEDI6383 and MEDI4736", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 39, "start_date": "2014-09-15", "completion_date": "2017-07-03", "has_results": false, "last_update_posted_date": "2019-03-13", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 7, "location_summary": "La Jolla, California • New Haven, Connecticut • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02221960" }, { "nct_id": "NCT01328626", "title": "A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "ABT-199", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 222, "start_date": "2011-05-23", "completion_date": "2020-05-08", "has_results": false, "last_update_posted_date": "2022-02-23", "last_synced_at": "2026-09-27T03:59:56.532Z", "location_count": 8, "location_summary": "Tucson, Arizona • La Jolla, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01328626" } ] }